
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9991/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:23 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9991 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9991 block--content--website-notice-block block--content--website-notice-block--9991 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9991 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9991 block--content--system-main-block block--content--system-main-block--9991 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9991 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001104659-24-024369.rtf%3b%20filename_%3dUTF-8%27%270001104659-24-024369.rtf" type="application/rtf" title="0001104659-24-024369.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001104659-24-024369.pdf%3b%20filename_%3dUTF-8%27%270001104659-24-024369.pdf" type="application/pdf" title="0001104659-24-024369.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001104659-24-024369.xls%3b%20filename_%3dUTF-8%27%270001104659-24-024369.xls" type="application/vnd.ms-excel" title="0001104659-24-024369.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001104659-24-024369.html" type="application/octet-stream" title="0001104659-24-024369-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srrk="../../../scholarrock.com/20240215">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_srrk_scholarrock.com_20240215 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20240215_20240215 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001727196 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:AmendmentFlag" id="ixv-228">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityCentralIndexKey" id="ixv-229">0001727196</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="#srrk-20240215.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-02-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-15</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_905_edei--DocumentType_c20240215__20240215_zS9ubzDEC5d7"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:DocumentType" id="ixv-249">8-K</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CURRENT REPORT</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of earliest event Reported): <span id="xdx_904_edei--DocumentPeriodEndDate_c20240215__20240215_zwjM40m6zQP7"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-250">February 15, 2024</ix:nonNumeric></span>
</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20240215__20240215_zPMWYZvv8Gqj"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityRegistrantName" id="ixv-251">Scholar Rock Holding Corporation</ix:nonNumeric></span></b></span><br/>
(Exact Name of Registrant as Specified in Charter)</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20240215__20240215_zgWVgJ1oAPQl"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-252">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 34%; text-align: center"><b><span id="xdx_907_edei--EntityFileNumber_c20240215__20240215_z6wE3R032h4g"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityFileNumber" id="ixv-253">001-38501</ix:nonNumeric></span></b></td>
    <td style="width: 33%; text-align: center"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240215__20240215_zUN0ASlUta9f"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityTaxIdentificationNumber" id="ixv-254">82-3750435</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction of Incorporation)</td>
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">(I.R.S. Employer Identification Number)</td></tr>
<tr style="vertical-align: top">
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td>
    <td rowspan="1">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20240215__20240215_zEGzCU1WVS2"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityAddressAddressLine1" id="ixv-255">301 Binney Street</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20240215__20240215_zvs4vLfrbmz2"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityAddressAddressLine2" id="ixv-256">3rd Floor</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20240215__20240215_zIVqhb3dyaQf"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityAddressCityOrTown" id="ixv-257">Cambridge</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20240215__20240215_zfQBdOSQdQO7"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityAddressStateOrProvince" id="ixv-258">MA</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20240215__20240215_zMyx9WhyEc76"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:EntityAddressPostalZipCode" id="ixv-259">02142</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">(Address of Principal Executive Offices) (Zip Code)</td></tr>
</table>
<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>(<span id="xdx_902_edei--CityAreaCode_c20240215__20240215_zrVl7waYc613"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:CityAreaCode" id="ixv-260">857</ix:nonNumeric></span>) <span id="xdx_908_edei--LocalPhoneNumber_c20240215__20240215_zuIeJEvgosBl"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:LocalPhoneNumber" id="ixv-261">259-3860</ix:nonNumeric></span></b></span></p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant's telephone
number, including area code)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or
former address, if changed since last report)</p>

<p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #000000; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">
<tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20240215__20240215_zwN7JzU0MZq2"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-262">&#168;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20240215__20240215_za1ZuZEorJll"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-263">&#168;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20240215__20240215_zaLkIIDh0upa"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="ixv-264">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20240215__20240215_zio5udv13AGj"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-265">&#168;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border: Black 1pt solid; padding: 1pt; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange
    on which registered</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20240215__20240215_zuedA1iwSjg4"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:Security12bTitle" id="ixv-266">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20240215__20240215_z5Tynsao7Tl9"><ix:nonNumeric contextRef="AsOf2024-02-15" name="dei:TradingSymbol" id="ixv-267">SRRK</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 1pt 1pt 1pt 5.4pt; vertical-align: middle; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20240215__20240215_zVKlkUPPVNS3">
    <ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-268">The Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>


<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR &#167;240.12b-2). Emerging growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20240215__20240215_zPGkcO3c85xa" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-02-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-269">&#168;</ix:nonNumeric></span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February&#160;15, 2024, the Board of Directors (the &#8220;Board&#8221;)
of Scholar Rock Holding Corporation (the &#8220;Company&#8221;), upon the recommendation of its Nominating and Corporate Governance Committee,
increased the size of the Board to eleven (11) directors and subsequently appointed Katie Peng to join the Board, effective February&#160;15,
2024, filling the vacancy created by the increase in the size of the Board. The Board determined that Ms.&#160;Peng is independent under
the listing standards of NASDAQ and the Company&#8217;s corporate governance guidelines. Ms.&#160;Peng will serve as a Class&#160;II director
with a term expiring at the annual meeting of stockholders to be held in 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a non-employee director, Ms.&#160;Peng will receive cash compensation
and an equity award for her Board service, in accordance with the Company&#8217;s non-employee director compensation policy, as amended
from time to time. Ms.&#160;Peng is not a party to any transaction with the Company that would require disclosure under Item 404(a)&#160;of
Regulation S-K, and there are no arrangements or understandings between Ms.&#160;Peng and any other persons pursuant to which she was
selected as a director. In addition, Ms.&#160;Peng will enter into an indemnification agreement with the Company consistent with the form
of the existing indemnification agreement entered into between the Company and its non-employee directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February&#160;15, 2024, Amir Nashat informed the Company that he
will not stand for reelection as a Class&#160;II director at the Company&#8217;s annual meeting of stockholders in 2024 (the &#8220;Annual
Meeting&#8221;). Mr.&#160;Nashat&#8217;s decision to not stand for reelection was not the result of any disagreement with the Company
or any matter relating to the Company&#8217;s operations, policies or practices. Mr.&#160;Nashat will continue to serve as a member of
the Board and a member of the Audit Committee of the Board (the &#8220;Audit Committee&#8221;) until the Annual Meeting. In connection
with Ms.&#160;Peng&#8217;s appointment as a member of the Board, the Board also appointed her to the Audit Committee, effective as of
the Annual Meeting, upon Mr.&#160;Nashat&#8217;s departure from the Board and the Audit Committee. Following the appointment of Ms.&#160;Peng,
the Company&#8217;s Audit Committee will consist of Joshua Reed (Chair), Richard Brudnick and Ms.&#160;Peng. The compositions of the Compensation
Committee, the Nominating and Corporate Governance Committee, and the Science,&#160;Innovation&#160;&amp; Technology Committee will remain
unchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February&#160;15, 2024, the Company issued a press release announcing
the appointment of Ms.&#160;Peng to the Board. A copy of this press release is furnished as Exhibit&#160;99.1 to this report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#tm246269d1_ex99-1.htm">99.1&#160;Press Release issued by the Company on February&#160;15, 2024, furnished hereto.</a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">104&#160;Cover Page&#160;Interactive Data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>Scholar Rock Holding Corporation</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt">Date: February&#160;15, 2024</td>
    <td style="padding-bottom: 1.5pt">By:</td>
    <td style="border-bottom: Black 1pt solid">/s/ Junlin Ho</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Junlin Ho</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>General Counsel&#160;&amp; Corporate Secretary</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> </body>

<!-- Mirrored from investors.scholarrock.com/node/9991/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:07:23 GMT -->
</html>
</XBRL>
<div><a name="tm246269d1_ex99-1.htm"></a></div><HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Scholar Rock Announces
the Addition of Katie Peng to Its Board of Directors and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Promotes Mo Qatanani,
Ph.D. to Chief Scientific Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">CAMBRIDGE, Mass.--(BUSINESS
WIRE)&mdash; <FONT>February&nbsp;15, 2024</FONT>-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical
company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases
where protein growth factors play a fundamental role, </FONT>today announced the appointment of Katie Peng to Scholar Rock&rsquo;s Board
of Directors and the promotion of Mo Qatanani, Ph.D., to Chief Scientific Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;We are pleased to welcome Katie to
Scholar Rock&rsquo;s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,&rdquo;
said David Hallal, Chairman of the Board of Scholar Rock. &ldquo;Katie brings deep commercial expertise in neurology and rare diseases
and has a strong understanding of SMA from her experience launching Evrysdi while she was a business unit head at Genentech. Katie joining
our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board
at this year&rsquo;s annual shareholder meeting. Amir has made significant contributions to the growth of Scholar Rock since joining the
board in 2012, and we extend our sincere gratitude to him for his unwavering dedication to the company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ms.&nbsp;Peng is an accomplished biotechnology
executive with over three decades of deep commercial experience in neurology and rare diseases, and she is currently the Chief Commercial
Officer at Denali Therapeutics. Prior to joining Denali, Ms.&nbsp;Peng managed a neurology, ophthalmology, immunology, and rare disease
portfolio representing approximately $14 billion in revenue at Genentech. She has successfully launched multiple products in neurology,
oncology, and rare disease, notably Evrysdi&reg; (risdiplam) at Genentech, a medicine used to treat spinal muscular atrophy (SMA) in adults
and children. Before that, Ms.&nbsp;Peng was at Roche Holding AG, where she was the General Manager of both Taiwan and Singapore, managing
the portfolio of over 30 products in the Asia Pacific region. Earlier in her career, she held multiple commercial roles at Amgen Inc.
and was a research scientist at Allergan plc. Ms.&nbsp;Peng holds an MBA from the Kelley School of Business,&nbsp;Indiana University and
a B.A. from the University of California, Berkeley. She also serves as a board member for California Life Sciences and Adicet Bio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;I am thrilled to join Scholar Rock&rsquo;s
Board of Directors as the company prepares for its first potential commercial launch of apitegromab. I look forward to working with the
team and sharing my experience and expertise to successfully bring apitegromab to people living with SMA,&rdquo; said Ms.&nbsp;Peng.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;In addition to having Katie join our
Board,&nbsp;I am excited by the continued progress of our preclinical programs, including additional work in developing SRK-439 for cardiometabolic
disorders. Mo has been a driving force in advancing our early-stage pipeline, especially the cardiometabolic program, and it is my pleasure
to announce his promotion to Chief Scientific Officer. He has been an outstanding leader of our research organization and a key member
of the leadership team,&rdquo; said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr.&nbsp;Qatanani joined Scholar Rock in 2021
and, since 2022, has been leading all research functions, including discovery biology, protein sciences&nbsp;&amp; antibody engineering,
nonclinical safety, and translational sciences. He brings over 15 years of discovery and translational research experience in developing
and advancing multiple therapeutic modalities in the neuromuscular and cardiometabolic disease areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Prior to Scholar Rock, Dr.&nbsp;Qatanani was
a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground
up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Before that, he held research positions
of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Dr.&nbsp;Qatanani holds a Ph.D. in Molecular and
Human Genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the Institute for Diabetes, Obesity and Metabolism
at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Scholar Rock is known for its pioneering
scientific research, particularly in the unparalleled selective targeting of the latent forms of growth factors, and I am proud to be
able to lead these efforts during this exciting stage of the company&rsquo;s growth, and to help translate this groundbreaking science
into transformative therapies that have the potential to improve peoples&rsquo; lives,&rdquo; said Dr.&nbsp;Qatanani.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Scholar Rock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock is a biopharmaceutical company that discovers, develops,
and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of
the transforming growth factor beta (TGF&beta;) superfamily of cell proteins and named for the visual resemblance of a scholar rock to
protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental.
Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease,
cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock is the only company to show clinical proof of concept
for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches
is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth
factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through
traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com
and follow @ScholarRock and on LinkedIn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Availability of Other Information About Scholar Rock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors and others should note that we communicate with our investors
and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations
and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well
as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information.
As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scholar Rock&reg; is a registered trademark of Scholar Rock,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &quot;forward-looking statements&quot;
within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar
Rock&rsquo;s future expectations, plans and prospects, including without limitation, Scholar Rock&rsquo;s expectations regarding its growth,
strategy, progress and development timing, the ability of any individual to affect the growth, strategy, and progress of&nbsp;Scholar
Rock, and the potential of its product candidates and proprietary platform.<I>&nbsp;</I>The use of words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo;
 &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;future,&rdquo; &ldquo;potential,&rdquo; or &ldquo;continue,&rdquo;
and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based
on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties
include, without limitation, Scholar Rock&rsquo;s ability to provide the financial support, resources and expertise necessary to identify
and develop product candidates on the expected timeline, the data generated from Scholar Rock&rsquo;s nonclinical and preclinical studies
and clinical trials, and Scholar Rock&rsquo;s ability to manage expenses and to obtain additional funding when needed to support its business
activities and establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed
in the section entitled &quot;Risk Factors&quot; in Scholar Rock&rsquo;s Quarterly Report on Form&nbsp;10-Q for the year ended&nbsp;September&nbsp;30,
2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&rsquo;s subsequent filings
with the&nbsp;Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&rsquo;s views only as of today
and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the
date of the release, and&nbsp;Scholar Rock&nbsp;undertakes no duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Scholar Rock:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investors&nbsp;&amp; Media</B></FONT><BR>
Rushmie Nofsinger<BR>
Scholar Rock<BR>
<U>rnofsinger@scholarrock.com</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<U>ir@scholarrock.com</U><BR>
857-259-5573</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Molly MacLeod<BR>
Scholar Rock<BR>
mmacleod@scholarrock.com<BR>
media@scholarrock.com<BR>
802-579-5995</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9991\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
